geo: agreed FTM was "second to none" on this board regarding the mechanism of action of Bavituximab. He was certainly a source of information for me. Understanding the mode of action (MOA) of a compound--how and why it works--is important, but the critical issue is proven efficacy and safety...and why (under what circumstances)it is sensible for a clinician to prescribe it. In "the early days" I recognized the clinical utility of Bavi (and Cotara), as did several other key posters...that is, that pursuit of this line of investigation and treatment made sense. It did then, and it does now. There is really little more to be said until management finds a way to unblock forward motion. The numbers are there. Many of the "old-timers" are silent now because there is simply not much left to be said. Who was it who always posted, "show us the money!"?
News 
Market Data 
Discover 
AI
